Tumor Necrosis Factor Inhibitor Drugs Market Report 2026

The tumor necrosis factor inhibitor drugs market size has grown steadily in recent years. It will grow from $42.47 billion in 2025 to $43.54 billion in 2026 at a compound annual growth rate (CAGR) of 2.5%. The growth in the historic period can be attributed to rising prevalence of autoimmune diseases, limited treatment options, increasing r&d in biologics, strong patent protection for leading tnfi drugs, growing awareness among patients and physicians.

The tumor necrosis factor inhibitor drugs market size is expected to see steady growth in the next few years. It will grow to $48.58 billion in 2030 at a compound annual growth rate (CAGR) of 2.8%. The growth in the forecast period can be attributed to expansion of biosimilars, advancements in precision medicine, increase in chronic disease population, adoption of digital health monitoring, development of next-generation delivery systems. Major trends in the forecast period include personalized tnf inhibitor therapies, biosimilar adoption and expansion, combination therapies with tnf inhibitors, home-based and self-administered treatments, advanced drug delivery systems.

The rising prevalence of autoimmune diseases is anticipated to drive the growth of the tumor necrosis factor inhibitor drugs market in the coming years. Autoimmune disorders occur when the body’s immune system mistakenly attacks and destroys healthy tissue. TNF inhibitor drugs are used to manage these disorders by preventing inflammation. These drugs help alleviate pain, swelling, and other symptoms by blocking the actions of substances that cause inflammation. For example, a report from the Mayo Clinic in January 2025 indicated that approximately 15 million people in the U.S. are estimated to have one or more of the 105 autoimmune diseases. As the prevalence of autoimmune conditions increases, so does the demand for TNF inhibitor drugs.

Leading companies in the TNF inhibitor drugs market are focusing on developing innovative solutions, such as interchangeable biosimilar TNF-inhibitor formulations, to address the growing need for cost-effective biologic therapies, improved patient access, and high-quality alternatives to branded TNF inhibitors. Interchangeable biosimilars are advanced biologic products designed to match the reference drug in terms of safety, purity, potency, and clinical effectiveness, while offering better affordability and broader availability compared to traditional branded biologics. For example, in May 2024, Teva Pharmaceuticals, a U.S.-based pharmaceutical company, partnered with Alvotech, a Luxembourg-based biotechnology company, to introduce SIMLANDI (adalimumab-ryvk) injection in the U.S. as an interchangeable biosimilar to Humira. This product is used to treat various autoimmune conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.

In September 2024, Tharimmune, a U.S.-based biopharmaceutical company focused on autoimmune and inflammatory diseases, collaborated with Intract Pharma to develop targeted oral drug delivery solutions. This partnership aims to convert biologic TNF-inhibitor therapy into a pill format for better patient convenience and adherence, with Intract Pharma utilizing its Soteria delivery platform to facilitate the oral administration of this traditionally injectable drug. Intract Pharma specializes in enabling the oral delivery of large-molecule biologics, such as monoclonal antibodies, through its proprietary platform.

Major companies operating in the tumor necrosis factor inhibitor drugs market are AbbVie Inc.,Amgen Inc.,Johnson & Johnson Services Inc.,Novartis International AG,Pfizer Inc.,Samsung Bioepis Co. Ltd.,Sanofi SA,Lupin Ltd.,Cadila Healthcare Ltd.,Aryogen Biopharma,Casi Pharmaceuticals,Celltrion Inc.,Hanall Biopharma,Intas Pharmaceuticals,Mylan N.V.,Sandoz International GmbH,Fresenius Kabi AG,Boehringer Ingelheim GmbH,Merck KGaA,Teva Pharmaceutical Industries Limited.

North America was the largest region in the tumor necrosis factor inhibitor drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the tumor necrosis factor (TNF) inhibitors drugs market report during the forecast period. The regions covered in the tumor necrosis factor inhibitor drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tumor necrosis factor inhibitor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the tumor necrosis factor inhibitor drugs market by increasing the cost of imported biologics, raw materials, and advanced manufacturing equipment. Regions like North America and Europe, which rely heavily on imports for key TNF inhibitors and biosimilars, are most affected. Hospital and retail pharmacy segments face higher procurement costs, while manufacturers may benefit indirectly by promoting local production and biosimilar adoption. Overall, tariffs drive both cost challenges and opportunities for domestic market growth.

The tumor necrosis factor inhibitor drugs market research report is one of a series of new reports that provides tumor necrosis factor inhibitor drugs market statistics, including tumor necrosis factor inhibitor drugs industry global market size, regional shares, competitors with a tumor necrosis factor inhibitor drugs market share, detailed tumor necrosis factor inhibitor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the tumor necrosis factor inhibitor drugs industry. This tumor necrosis factor inhibitor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

TNF inhibitor drugs are medications designed to prevent inflammation. These drugs are commonly used to treat inflammatory and autoimmune diseases by inhibiting the inflammatory response caused by TNF cytokines.

The key TNF inhibitor drugs available on the market include Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, and biosimilars. Humira is a TNF blocker that helps reduce the effects of substances in the body that contribute to inflammation. It can be administered through subcutaneous or intravenous injection. Distribution channels for these drugs include hospital pharmacies, retail pharmacies, and online pharmacies, and they are used in the treatment of conditions such as rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa, and more.

The tumor necrosis factor (TNF) inhibitors drugs market consists of sales of enbrel, ereizi, inflectra, and renflexis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.